Conference Program

Thursday, September 24

7:00 p.m.–8:00 p.m. **Opening Keynote Session**
Ellington Ballroom
Session Chairperson: Charles W.M. Roberts, St. Jude Children's Research Hospital, Memphis, TN

Welcome remarks
Charles W.M. Roberts

Keynote Address
Epigenetic mechanisms of tumor initiation and evolution
Bradley E. Bernstein, Massachusetts General Hospital, Harvard Medical School, Boston, MA

8:00 p.m.–9:30 p.m. **Welcome Reception**
Overlook

Friday, September 25

7:00 a.m.–8:00 a.m. **Continental Breakfast**
Terrace and Ellington Prefunction

8:00 a.m.–10:00 a.m. **Plenary Session 1: Epigenetic Regulation of Transcription Initiation**
Ellington Ballroom
Session Chairperson: Peter A. Jones, Van Andel Research Institute, Grand Rapids, MI

8:00 a.m. **Genomic organization of yeast chromatin and gene regulatory complexes**
B. Franklin Pugh, Penn State University, University Park, PA

8:30 a.m. **Elucidating and targeting dichotomous roles of the PRC2 complex in cancer**
Karen M. Cichowski, Brigham and Women's Hospital, Boston, MA

9:00 a.m. **How DNA methylation organizes the cancer epigenome**
Peter A. Jones

9:30 a.m. **Structural mechanism of sequence-specific 5-methylcytosine (5mC) recognition by AP-1 transcription factors***
Samuel Hong, Emory University, Atlanta, GA

9:45 a.m. **Transcriptional regulation mediated by biochemically distinct forms of SWI/SNF***
Jesse R. Raab, University of North Carolina at Chapel Hill, Chapel Hill, NC

*Short talks from proffered papers

10:00 a.m.-10:30 a.m. **Break**
Ellington Prefunction

10:30 a.m.-12:30 p.m. **Plenary Session 2: Enhancers, Epigenetics, and Cancer**
Ellington Ballrrom
Session Chairperson: Charles W.M. Roberts, St. Jude Children's Research Hospital, Memphis, TN

10:30 a.m. **Genome-wide views into the mechanisms of transcription regulation**
John T. Lis, Cornell University, Ithaca, NY

11:00 a.m. **SWI/SNF chromatin remodeling complex mutations in cancer: Mechanisms and potential therapeutic insights**
Charles W.M. Roberts

11:30 a.m. **Decoding the cancer regulome**
John Stamatoyannopoulos, University of Washington, Seattle, WA

12:00 p.m. **Exploring the link between Kras and histone acetylation***
Alessandro Carrer, Abramson Family Cancer Research Institute, Philadelphia, PA

12:15 p.m. **Targeting super-enhancer driven oncogene transcription through cyclin-dependent kinase inhibitors***
Rani E. George, Dana-Farber Cancer Institute, Boston, MA

12:30 p.m.-2:30 p.m. **Poster Session A with Lunch**
Overlook

2:30 p.m.-4:30 p.m. **Plenary Session 3: Control of Transcription and Elongation**
Ellington Ballroom
Session Chairperson: Karen Adelman, Laboratory of Epigenetics and Stem Cell Biology, National Institute of Environmental Health Sciences, Research Triangle Park, NC

2:30 p.m. **An epigenome perspective of human tumor evolution**
Joseph F. Costello, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

3:00 p.m. **Nucleosome barriers to transcription**
Steven Henikoff, Fred Hutchinson Cancer Research Center, Seattle, WA

3:30 p.m. **Regulating transcription elongation at stimulus responsive genes**
Karen Adelman

4:00 p.m. **Using epigenetic profiling and CRISPR screens to understand cancer progression**
X. Shirley Liu, Dana-Farber Cancer Institute, Boston, MA

4:30 p.m.- **Evening on Own**

*Short talks from proffered papers

7:00 a.m.-8:00 a.m. **Continental Breakfast**
Terrace and Ellington Prefunction

8:00 a.m.-10:00 a.m. **Plenary Session 4: Chromatin Organization**
Ellington Ballroom
Session Chairperson: Sharon Y.R. Dent, The University of Texas MD Anderson Cancer Center, Smithville, TX

8:00 a.m. **Long-range gene regulation in the context of chromatin domains**
Job Dekker, University of Massachusetts Medical School, Worcester, MA

8:30 a.m. **Structure and function of BAF complexes in human cancer**
Cigall Kadoch, Dana-Farber Cancer Institute, Boston, MA

9:00 a.m. **A SAGA of GCN5 and USP22 in development and disease**
Sharon Y.R. Dent

9:30 a.m. **Mechanisms of ATP-dependent chromatin remodeling**
Geeta Narlikar, University of California at San Francisco, San Francisco, CA

10:00 a.m.-10:30 a.m. **Break**
Ellington Prefunction

10:30 a.m.-12:30 p.m. **Plenary Session 5: ncRNAs and Cancer**
Ellington Ballroom
Session Chairperson: Ramin Shiekhattar, University of Miami Miller School of Medicine, Miami, FL

10:30 a.m. **The impact of cohesin mutations in tumor initiation: One ring, many functions**
Iannis Aifantis, HHMI/NYU School of Medicine, New York, NY

11:00 a.m. **Biogenesis and mechanism of action of enhancer RNAs**
Ramin Shiekhattar

11:30 a.m. **Functional characterization of the tumor suppressor lysine-specific methyltransferase KMT2D in lymphoma**
Hans-Guido Wendel, Memorial Sloan Kettering Cancer Center, New York, NY

12:00 p.m. **"Viral mimicry" as a mechanism of action for DNA-demethylating agents***
Daniel De Carvalho, Princess Margaret Cancer Centre, Toronto, ON, Canada

12:15 p.m. **Analysis of enhancer transcription reveals novel gene regulatory networks in breast cancer***
Hector L. Franco, The Cecil H. and Ida Green Center for Reproductive Biology Sciences, UT Southwestern Medical Center, Dallas, TX

12:30 p.m.-2:30 p.m. **Lunch on own/Free Time**

*Short talks from proffered papers

2:30 p.m.-4:30 p.m. **Plenary Session 6: Cancer Genomics and Epigenomics**
Ellington Ballroom
Session Chairperson: Suzanne J. Baker, St. Jude Children's Research Hospital, Memphis, TN

2:30 p.m. **Integrative epigenomic analysis across cancer types**
Peter W. Laird, Van Andel Research Institute, Grand Rapids,MI

3:00 p.m. **The oncogenic role of histone H3 mutations in pediatric high-grade gliomas**
Suzanne J. Baker

3:30 p.m. **The cell-type specific effect of epigenomic features on cancer mutation**
Shamil Sunyaev, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

4:00 p.m. **The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains***
Erica M. Walsh, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

4:15 p.m. **GC skew defines distinct RNA polymerase pause sites in CpG island promoters***
Joshua S.K. Bell, Emory University, Atlanta, GA

4:30 p.m.-6:30 p.m. **Poster Session B and Reception**
Overlook

6:30 p.m.- **Evening on Own**

*Short talks from proffered papers

7:00 a.m.-8:00 a.m. **Continental Breakfast**
Terrace and Ellington Prefunction

8:00 a.m.-10:00 a.m. **Plenary Session 7: Epigenetic Cancer Therapies 1**
Ellington Ballroom
Session Chairperson: Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD

8:00 a.m. **Targeting DNA methylation abnormalities as a cancer therapy strategy**
Stephen B. Baylin

8:30 a.m. **Multiple targetable pathways for epigenetic therapy**
Jean-Pierre Issa, Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, PA

9:00 a.m. **Discovery of novel epigenetic targets**
Frank Stegmeier, Novartis, Cambridge, MA

9:30 a.m. **EZH2 inhibitors reveal broad EZH2 dependencies in multiple myeloma***
Shilipi Arora, Constellation Pharmaceuticals, Cambridge, MA
This talk is not not accredited for CME credit to permit the free flow of information of the commercial interest employees participating.

9:45 a.m. **A DNA hypomethylation signature predicts novel anti-tumor activity of LSD1 inhibition in SCLC***
Helai Mohammad, GlaxoSmithKline, Collegeville, PA
This talk is not not accredited for CME credit to permit the free flow of information of the commercial interest employees participating.

10:00 a.m.-10:15 a.m. **Break**
Ellington Prefunction

*Short talks from proffered papers

10:15 a.m.–12:15 p.m. **Plenary Session 8: Epigenetic Cancer Therapies 2**
Ellington Ballroom
Session Chairperson: Ari M. Melnick, Weill Cornell Medical College of Cornell University, New York, NY

10:15 a.m. **Epigenetics switches enabling transformation of B cells**
Ari M. Melnick

10:45 a.m. **Next-generation bromodomain inhibitors**
James E. Bradner, Dana-Farber Cancer Institute, Boston, MA

11:15 a.m. **Tazemetostat, an EZH2 Inhibitor and potential therapeutic for non-Hodgkin lymphoma**
Jesse J. Smith, Epizyme, Inc., Waltham, MA

11:45 a.m. **A bromodomain cassette exchange strategy establishes that on-target chemical inhibition of BRD9 limits leukemia cell proliferation***
Anja F. Hohmann, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

12:00 p.m. **MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy drugs***
Wei Xu, University of Wisconsin, Madison, WI

*Short talks from proffered papers